FDA Approves Breztri Aerosphere as COPD Maintenance Treatment
AstraZeneca‘s Breztri Aerosphere has been approved by the U.S. Food and Drug Administration (FDA) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Formerly known as PT010, Breztri Aerosphere is an inhaled therapy with three active components: the long-acting muscarinic antagonist…